IMPROVE-IT

Summary: Evaluated ezetimibe with simvastatin 10/40 mg PO daily versus simvastatin alone. The primary endpoint is cardiovascular events, major coronary events and stroke. No results are available for this trial.

Original Publication:

None

Eponym: The IMPROVEd Reduction of Outcomes: Vytorin Efficacy International Trial